There is an ongoing explosion of knowledge in the immunological sciences with the discovery of many agents that have the potential to serve as immunotherapeutic drugs. For a variety of reasons, few of these are being tested in humans. The workshop developed a ranked list of agents with high potential for use in treating cancer. Despite substantial demonstrated immunological efficacy, these agents are not broadly available for testing in patients with cancer. The ranking by workshop participants was based on the likelihood for efficacy in cancer therapy and was exceedingly well-vetted, with broad and substantial input. The exceedingly broad nature of the consensus behind this list will facilitate subsequent NCI discussions on the availability of clinical grade immunotherapeutic drugs for human trials and will inform other governmental agencies, nongovernmental funding agencies, industry, and individual investigators that these agents have broad appeal to the immunotherapy community and, by consensus, hold particular promise for use in cancer therapy.National Cancer Institute Immunotherapy Agent Workshop Proceedings - July 12th, 2007#SITCPublication